Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Versant Venture Management LLC

Versant Venture Management LLC reduced its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 27.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,180,780 shares of the company’s stock after selling 1,201,907 shares during the period. Monte Rosa Therapeutics makes up 37.0% of Versant Venture Management LLC’s holdings, making the stock its biggest position. Versant Venture Management LLC’s holdings in Monte Rosa Therapeutics were worth $52,324,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GLUE. GAMMA Investing LLC purchased a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth $30,000. Russell Investments Group Ltd. purchased a new position in shares of Monte Rosa Therapeutics during the 3rd quarter worth $32,000. Lazard Asset Management LLC boosted its stake in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after buying an additional 3,262 shares during the period. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE opened at $23.41 on Thursday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -15.82 and a beta of 1.56. The firm has a 50-day simple moving average of $20.01 and a 200-day simple moving average of $19.27. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. Equities research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on GLUE shares. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. JPMorgan Chase & Co. upped their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Zacks Research lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company reduced their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and an average price target of $33.33.

Insider Activity

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $231,100. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the transaction, the insider directly owned 67,845 shares of the company’s stock, valued at $1,581,466.95. This represents a 8.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,778 shares of company stock valued at $1,768,581 over the last ninety days. 6.40% of the stock is owned by company insiders.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.